FI/EP 2 630 962 Rajoitetut patenttivaatimukset englannin kielellä

1. Glatiramer acetate in the form of a pharmaceutical composition for use in treating a human patient suffering from relapsing-remitting multiple sclerosis in a regimen of three subcutaneous injections of a 40 mg dose of glatiramer acetate every week with at least one day between every subcutaneous injection and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range of 5.5 to 7.0.

2. Glatiramer acetate in the form of a pharmaceutical composition for use of claim 1, which reduces brain atrophy.

3. Glatiramer acetate in the form of a pharmaceutical composition for use of any one of claims 1 or 2, wherein the human patient has not received glatiramer acetate therapy prior to initiation of the treatment.